Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GPR139 | Q6DWJ6 | 6/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14291771 | 0.92 | TRPV1 (0.58) | TRPV1MAPK1GPR139CYP3A4CYP2D6 | |
| SCHEMBL306501 | 0.92 | TRPV1 (0.58) | TRPV1MAPK1GPR139CYP3A4CYP2D6 | |
| SCHEMBL29454367 | 0.92 | TRPV1 (0.58) | TRPV1MAPK1GPR139CYP3A4CYP2D6 | |
| SCHEMBL308305 | 0.92 | TRPV1 (0.58) | TRPV1MAPK1GPR139CYP3A4CYP2D6 | |
| SCHEMBL306502 | 0.92 | TRPV1 (0.58) | TRPV1MAPK1GPR139CYP3A4CYP2D6 | |
| SCHEMBL4492187 | 0.92 | TRPV1 (0.83) | TRPV1MAPK1GPR139CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL29454378 | 0.91 | TRPV1 (0.57) | TRPV1MAPK1GPR139CYP3A4CYP2D6 | |
| SCHEMBL2695127 | 0.91 | TRPV1 (0.59) | TRPV1MAPK1GPR139ARENPP2 | |
| SCHEMBL2694475 | 0.91 | TRPV1 (0.59) | TRPV1MAPK1GPR139ARENPP2 | |
| SCHEMBL2692682 | 0.90 | TRPV1 (0.53) | TRPV1MAPK1GPR139CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168668-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-05-01 | — | — | US | claimed |
| EP-1966156-B1 | NEW COMPOUNDS III | ASTRAZENECA AB (SE) | 2011-12-21 | — | — | EP | claimed |
| US-20100286202-A1 | New Compounds | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | US | claimed |
| EP-1966156-A2 | NEW COMPOUNDS III | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | claimed |
| US-20080171770-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | claimed |
| WO-2007073303-A2 | NOVEL BENZIMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR 1 (VRL) INHIBITORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | claimed |
| US-8168668-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-05-01 | — | — | US | disclosed |
| EP-1966156-B1 | NEW COMPOUNDS III | ASTRAZENECA AB (SE) | 2011-12-21 | — | — | EP | disclosed |
| US-20100286202-A1 | New Compounds | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | US | disclosed |
| US-7618993-B2 | Compounds | ASTRAZENECA AB (SE) | 2009-11-17 | — | — | US | disclosed |
| EP-1966156-A2 | NEW COMPOUNDS III | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| US-20080171770-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2007073303-A2 | NOVEL BENZIMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR 1 (VRL) INHIBITORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286202-A1 | New Compounds | REN, PCSK9, FURIN | TRPV1 117/4885MAPK1 3756/4885GPR139 1736/4885 |
| US-20080171770-A1 | Compounds | REN, PCSK9, SLC10A1 | TRPV1 91/4885MAPK1 3790/4885GPR139 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.